Abstract
We aimed to refine the hypothesis that Motoric Cognitive Risk (MCR), a syndrome combining measured slow gait speed and self-reported cognitive complaints, is prognostic of incident dementia and other major causes of morbidity in older age. We propose mechanisms on the relationship between motor and cognitive function and describe a roadmap to validate these hypotheses. We systematically searched major electronic databases from inception to August 2021 for original longitudinal cohort studies of adults aged ≥60 years that compared an MCR group to a non-MCR group with any health outcome. Fifteen cohorts were combined by meta-analysis. Participants with MCR were at an increased risk of cognitive impairment (adjusted hazard ratio [aHR] 1.76, 95%CI 1.49-2.08; I2=24.9%), dementia (aHR 2.12, 1.85-2.42; 33.1%), falls (adjusted Relative Risk 1.38, 1.15-1.66; 62.1%), and mortality (aHR 1.49, 1.16-1.91; 79.2%). The prognostic value of MCR is considerable and mechanisms underlying the syndrome are proposed.
Systematic review registration PROSPERO CRD42020225183.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=225183
Funding Statement
The present manuscript received no direct funding. All funded researchers are independent of their funders with payments to institution. AC has no funding to declare. DSM is undertaking a PhD Clinical Research Fellowship funded by a one-off grant from the Masonic Charitable Foundation and the Royal College of Psychiatrists, United Kingdom. MW is funded by an Age UK grant for PhD studentship. ML is funded by a Biotechnology and Biological Sciences Research Council (BBSRC) project grant and is a previous recipient of the Moray Award for travel from University of Edinburgh. TCR is Principal Investigator Chief Scientist Office. TCR occasionally completes medicolegal reports for Solicitors in Edinburgh. These payments are made to him but relate solely to his clinical work and not the academic work under review. TCR receives NHS study leave expenses (travel, accommodation, and registration). GMT is funded by the Medical Research Council methodology board and received consulting fees for an NIH funded grant.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: The present manuscript received no direct funding. All funded researchers are independent of their funders with payments to institution. AC has no funding to declare. DSM is undertaking a PhD Clinical Research Fellowship funded by a one-off grant from the Masonic Charitable Foundation and the Royal College of Psychiatrists, United Kingdom. MW is funded by an Age UK [MR/M01311/1] grant for PhD studentship. ML is funded by a Biotechnology and Biological Sciences Research Council (BBSRC) project grant and is a previous recipient of the Moray Award for travel from University of Edinburgh. TCR is Principal Investigator 2021– 2024 £1,518,000 grant, Chief Scientist Office: “NRS Neuroprogressive and Dementia Network” 2021–22 £216,666 grant, UKRI: “Sharing the diagnosis of dementia in the post-Covid clinic: patient and practitioner perspectives” 2019-21 £10,394 Catalytic grant, CSO: “Playlist for Life: Can personalised music be rapidly implemented in care homes as a non-pharmacological intervention for dementia?” 2017–18 £56,519 grant, NERC-MRC-CSO: “Modelling historical air pollution and dementia/cognitive decline – towards a life course approach” 2016-2021 £750,000 grant from Alzheimer Scotland for Phase 2 of the Alzheimer Scotland Dementia Research Centre Co-investigator 2019-2021 £733,246 Research grant, MRC: “Brain imaging and cognitive ageing in the Lothian Birth Cohort 1936: IV” 2017-18 $40,000 from the Japan Agency for Medical Research and Development / New York Academy of Sciences Interstellar Initiative. TCR occasionally completes medicolegal reports for Solicitors in Edinburgh. These payments are made to him but relate solely to his clinical work and not the academic work under review. TCR receives NHS study leave expenses (travel, accommodation, and registration). GMT is funded by the Medical Research Council methodology board and received consulting fees for an NIH-funded grant.
Declarations of interest: MW is vice-chair of the Scotland Research Ethics Committee. TCR has participated on the Alzheimer’s Society and Alzheimer Scotland Advisory Boards - no payment. No other authors claim any disclosure.
Selected aspects of the present manuscript were presented in preliminary form as a poster at the 2021 Alzheimer’s Association International Conference, online.
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.